Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.96
(30.67%)
USD 1.96
(30.67%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 316.61 Million USD | 84.56% |
| 2021 | 171.54 Million USD | -8.66% |
| 2020 | 187.8 Million USD | -4.13% |
| 2019 | 195.89 Million USD | -8.17% |
| 2018 | 213.31 Million USD | -9.88% |
| 2017 | 236.7 Million USD | 24.92% |
| 2016 | 189.48 Million USD | 186.11% |
| 2015 | 66.22 Million USD | 246.76% |
| 2014 | 19.09 Million USD | 39.62% |
| 2013 | 13.67 Million USD | 438.75% |
| 2012 | 2.53 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q2 | 64.64 Million USD | -2.5% |
| 2023 Q1 | 66.3 Million USD | 9.24% |
| 2022 Q1 | 115.87 Million USD | 173.8% |
| 2022 FY | 316.61 Million USD | 84.56% |
| 2022 Q2 | 74.13 Million USD | -36.02% |
| 2022 Q3 | 65.9 Million USD | -11.11% |
| 2022 Q4 | 60.69 Million USD | -7.89% |
| 2021 FY | 171.54 Million USD | -8.66% |
| 2021 Q3 | 39.85 Million USD | -17.19% |
| 2021 Q4 | 42.32 Million USD | 6.19% |
| 2021 Q2 | 48.12 Million USD | 16.67% |
| 2021 Q1 | 41.24 Million USD | -17.36% |
| 2020 Q3 | 49.92 Million USD | 19.05% |
| 2020 Q1 | 46.02 Million USD | -4.64% |
| 2020 Q2 | 41.93 Million USD | -8.87% |
| 2020 Q4 | 49.91 Million USD | -0.02% |
| 2020 FY | 187.8 Million USD | -4.13% |
| 2019 Q2 | 56.7 Million USD | 13.89% |
| 2019 Q4 | 48.25 Million USD | 17.28% |
| 2019 Q3 | 41.14 Million USD | -27.43% |
| 2019 FY | 195.89 Million USD | -8.17% |
| 2019 Q1 | 49.78 Million USD | -11.18% |
| 2018 Q3 | 51.33 Million USD | -13.42% |
| 2018 Q2 | 59.29 Million USD | 27.17% |
| 2018 Q1 | 46.62 Million USD | -0.34% |
| 2018 FY | 213.31 Million USD | -9.88% |
| 2018 Q4 | 56.05 Million USD | 9.19% |
| 2017 Q4 | 46.78 Million USD | -25.76% |
| 2017 Q2 | 50.1 Million USD | -34.75% |
| 2017 Q1 | 76.79 Million USD | -5.36% |
| 2017 FY | 236.7 Million USD | 24.92% |
| 2017 Q3 | 63.02 Million USD | 25.77% |
| 2016 Q1 | 29.59 Million USD | 62.76% |
| 2016 Q4 | 81.14 Million USD | 114.47% |
| 2016 Q3 | 37.83 Million USD | -7.54% |
| 2016 Q2 | 40.91 Million USD | 38.28% |
| 2016 FY | 189.48 Million USD | 186.11% |
| 2015 Q4 | 18.18 Million USD | 216.96% |
| 2015 FY | 66.22 Million USD | 246.76% |
| 2015 Q3 | 5.73 Million USD | -4.43% |
| 2015 Q2 | 6 Million USD | -83.47% |
| 2015 Q1 | 36.3 Million USD | 548.38% |
| 2014 Q3 | 2.81 Million USD | -51.47% |
| 2014 FY | 19.09 Million USD | 39.62% |
| 2014 Q4 | 5.6 Million USD | 99.22% |
| 2014 Q2 | 5.79 Million USD | 15.73% |
| 2014 Q1 | 5 Million USD | -8.86% |
| 2013 Q2 | 5.07 Million USD | 104.57% |
| 2013 Q1 | 2.48 Million USD | 67.28% |
| 2013 Q3 | 4.63 Million USD | -8.57% |
| 2013 FY | 13.67 Million USD | 438.75% |
| 2013 Q4 | 5.49 Million USD | 18.35% |
| 2012 Q3 | 1.3 Million USD | 0.0% |
| 2012 Q4 | 1.48 Million USD | 13.55% |
| 2012 FY | 2.53 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bright Green Corporation | 401.49 Thousand USD | -78758.555% |
| BioQuest Corp. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -1717.822% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -2484.877% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | - USD | -Infinity% |
| Instadose Pharma Corp. | - USD | -Infinity% |